1-5 of 5
Matteo Giovanni Della Porta
Close
Sort by
Journal Articles

Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting

Enrico Attardi, Arianna Savi, Beatrice Borsellino, Alfonso Piciocchi, Marta Cipriani, Tiziana Ottone, Emiliano Fabiani, Mariadomenica Divona, Serena Travaglini, Maria Rosaria Pascale, Hussein Awada, Arda Durmaz, Valeria Visconte, Matteo Giovanni Della Porta, Adriano Venditti, Jaroslaw P. Maciejewski, Carmelo Gurnari, Maria Teresa Voso
Journal: Blood Advances
Blood Adv (2023) 7 (17): 5122–5131.
https://doi.org/10.1182/bloodadvances.2023010173
Published: 2023
Includes: Supplemental data
Journal Articles

MGUS and clonal hematopoiesis show unrelated clinical and biological trajectories in an older population cohort

Matteo Claudio Da Vià, Marta Lionetti, Alessio Marella, Antonio Matera, Erica Travaglino, Elena Signaroldi, Alessia Antonella Galbussera, Ugo Lucca, Sara Mandelli, Emma Riva, Mauro Tettamanti, Loredana Pettine, Alessandra Pompa, Luca Baldini, Antonino Neri, Matteo Giovanni Della Porta, Niccolò Bolli
Journal: Blood Advances
Blood Adv (2022) 6 (21): 5702–5706.
https://doi.org/10.1182/bloodadvances.2021006498
Published: 2022
Includes: Supplemental data
Journal Articles

A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis

Clinical Trials & Observations
Margherita Maffioli, Barbara Mora, Somedeb Ball, Alessandra Iurlo, Elena Maria Elli, Maria Chiara Finazzi, Nicola Polverelli, Elisa Rumi, Marianna Caramella, Maria Cristina Carraro, Mariella D’Adda, Alfredo Molteni, Cinzia Sissa, Francesca Lunghi, Alessandro Vismara, Marta Ubezio, Anna Guidetti, Sabrina Caberlon, Michela Anghilieri, Rami Komrokji, Daniele Cattaneo, Matteo Giovanni Della Porta, Toni Giorgino, Lorenza Bertù, Marco Brociner, Andrew Kuykendall, Francesco Passamonti
Journal: Blood Advances
Blood Adv (2022) 6 (6): 1855–1864.
https://doi.org/10.1182/bloodadvances.2021006889
Published: 2022
Includes: Supplemental data
Journal Articles

CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML

Bérengère Salomé, Alejandra Gomez-Cadena, Romain Loyon, Madeleine Suffiotti, Valentina Salvestrini, Tania Wyss, Giulia Vanoni, Dan Fu Ruan, Marianna Rossi, Alessandra Tozzo, Paolo Tentorio, Elena Bruni, Carsten Riether, Eva-Maria Jacobsen, Peter Jandus, Curdin Conrad, Manfred Hoenig, Ansgar Schulz, Katarzyna Michaud, Matteo Giovanni Della Porta, Silvia Salvatore, Ping-Chih Ho, David Gfeller, Adrian Ochsenbein, Domenico Mavilio, Antonio Curti, Emanuela Marcenaro, Alexander Steinle, Amir Horowitz, Pedro Romero, Sara Trabanelli, Camilla Jandus
Journal: Blood Advances
Blood Adv (2019) 3 (22): 3674–3687.
https://doi.org/10.1182/bloodadvances.2018030478
Published: 2019
Includes: Supplemental data
Journal Articles

Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients

Clinical Trials & Observations
Margherita Maffioli, Toni Giorgino, Barbara Mora, Alessandra Iurlo, Elena Elli, Maria Chiara Finazzi, Marianna Caramella, Elisa Rumi, Maria Cristina Carraro, Nicola Polverelli, Mariella D’Adda, Simona Malato, Marianna Rossi, Alfredo Molteni, Alessandro Vismara, Cinzia Sissa, Francesco Spina, Michela Anghilieri, Daniele Cattaneo, Rossella Renso, Marta Bellini, Maria Luisa Pioltelli, Chiara Cavalloni, Daniela Barraco, Raffaella Accetta, Lorenza Bertù, Matteo Giovanni Della Porta, Francesco Passamonti
Journal: Blood Advances
Blood Adv (2019) 3 (21): 3196–3200.
https://doi.org/10.1182/bloodadvances.2019000646
Published: 2019
Includes: Supplemental data